"Sebia India will introduce pipeline of new products across Autoimmunity, Infectious Diseases"

France headquartered Sebia, a global leader in specialty diagnostics, is continuing its geographic footprint to better serve its customers. Over the decades, the company has earned worldwide recognition for its pioneering expertise in Multiple Myeloma screening, diagnosis, and monitoring, as well as its leadership in hemoglobinopathies diagnosis. In recent years, Sebia has significantly expanded its portfolio in autoimmunity and infectious disease diagnostics through strategic acquisitions – ORGENTEC in 2021 and ZEUS Scientific in 2022. The company is now all set to strengthen its presence in India, thereby expanding its reach, building talent, and raising awareness. Sebia established its presence in India in 2019, and has achieved consistent double-digit growth year after year. To find out more about the company's growth plans in India, BioSpectrum spoke to Heejin Roh, Vice President – Commercial Operations, Asia Pacific, Sebia. Edited excerpts:

- Dr Manbeena Chawla

Please share details of the new initiatives to be taken to strengthen the company's presence in India.

From next year, we will be focusing on both geographic expansion and talent development. A new branch office will soon be inaugurated in Mumbai, strengthening our regional presence and customer engagement. The office in Mumbai has been designed as a co-working hub for our field employees. Since our team members are often on the move, this will provide them with a professional base to connect and collaborate. At the same time, Sebia India is committed to nurturing young talent in the diagnostics industry through structured training programmes, mentorship initiatives, and leadership development, ensuring we build the next generation of diagnostics professionals. Besides, Sebia India is committed to introducing an exciting pipeline of new products across Autoimmunity, Infectious Diseases and bringing innovative diagnostic solutions closer to our customers. This combined approach of innovation, expansion, and talent development will help us build a stronger foundation for the next generation of diagnostics professionals in India.

Which are the major therapeutic areas that Sebia India is focusing on?

Our core focus remains on areas of high clinical importance and unmet need. These include the screening, diagnosis and monitoring of Multiple Myeloma, Diabetes, Hemoglobinopathies & Thalassemia and Autoimmune disorders.

Are you planning to launch new products or technologies for the Indian market in 2026 and beyond? How cost-effective are these compared to competitors?